-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau to present Alpha DaRT-pembrolizumab head and neck cancer trial data at AHNS 2026

PUBT·05/05/2026 13:05:41
Listen to the news
Alpha Tau to present Alpha DaRT-pembrolizumab head and neck cancer trial data at AHNS 2026
  • Alpha Tau Medical announced podium presentation of complete top-line results from study testing Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma.
  • Data were previously shown in interim form at R&D Day in January 2025, with full results scheduled for AHNS 12th International Conference on Head and Neck Cancer in Boston on July 21, 2026.
  • Update supports strategy to pair localized intratumoral radiotherapy with checkpoint immunotherapy, targeting patients who often cannot tolerate standard aggressive regimens.
  • Company highlighted safety profile across prior head and neck studies, positioning combination approach as a potential add-on that does not disrupt ongoing systemic immunotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051929), on May 05, 2026, and is solely responsible for the information contained therein.